How to appeal a UnitedHealthcare plaque psoriasis + psoriatic arthritis denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for plaque psoriasis + psoriatic arthritis

Cited policy: OptumRx Skyrizi (Risankizumab) Plaque + PsA PA

Plaque: BSA >=3% OR special-site involvement (face/genital/scalp/palms/soles/nails). Trial + failure or intolerance of >=1 conventional systemic (MTX/CsA/acitretin) OR phototherapy OR oral PDE-4. PsA: ACR criteria + active disease (TJC >=3 SJC >=3 or axial/enthesitis/dactylitis). Step-therapy may require Humira/biosimilar first unless contraindicated. Reauth at 6 mo with PASI 75 / sPGA 0-1 or ACR20.

How UnitedHealthcare denies plaque psoriasis + psoriatic arthritis — and how to counter it

Where UnitedHealthcare pushes back: 1) Step-therapy: must fail TNFi/biosimilar first; 2) BSA <3% without special-site; 3) No conventional systemic trial documented; 4) Reauth without objective PASI/ACR20.

Counter-arguments that hold up: AAD-NPF 2019 (Menter JAAD) endorses TNFi + IL-17 + IL-23 as PARALLEL first-line systemics — no mandated TNFi-first. Special-site involvement (scalp/genital/nails/palms/soles) bypasses BSA per AAD-NPF 2019. UltIMMa-1/-2 Lancet 2018 — PASI 90 75% wk 16. IMMVENT (Skyrizi vs Humira) — PASI 90 72% Skyrizi vs 47% Humira wk 44. KEEPsAKE-1 + KEEPsAKE-2 ARD 2022 — ACR20 ~57% PsA. FDA Apr 2019 plaque + Jan 2022 PsA. Primary TNFi failure predicts second-TNFi failure — class switch appropriate per GRAPPA 2021.

What UnitedHealthcare typically denies for plaque psoriasis + psoriatic arthritis

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For plaque psoriasis + psoriatic arthritis, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the plaque psoriasis + psoriatic arthritis treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira
• Enbrel
• Remicade
• Cimzia
• Simponi
• Cosentyx

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.